MICHAEL A. CALIGIURI, M.D.
Osteopathic Medicine at 10 Ave, Columbus, OH

2004003, Feb 26, 2004

Dec 9, 2002

10/314869

Matthew Platz - Columbus OH, US
Michael Caligiuri - Upper Arlington OH, US
Susan Olesik - Dublin OH, US
Helene Balladur - Columbus OH, US
Jacqueline Ward - Columbus OH, US

C12N015/86, C12N007/00

435/235100, 435/239000, 435/456000

Cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes, and methods of producing cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes are provided. The methods comprise transforming B lymphocytes with EBV, incubating the transformed B lymphocytes with a flavin photosensitizer, such as riboflavin or a lumichrome-resistant photosenstizer, adding a non-toxic anti-oxidant, and exposing the lymphocytes to photoradiation of an appropriate wavelength to activate the photosensitizer. Also provided are methods of using the apoptotic EBV-transformed B lymphocyte cell preparations to elicit production of EBV-specific T cells in human patients. Finally, methods of treating organ transplant patients comprising administering an effective amount of the apoptotic EBV-transformed B-lymphocytes cell preparation to the patients prior to transplantation are provided.

2008015, Jul 3, 2008

Aug 2, 2007

11/888699

Michael A. Caligiuri - Columbus OH, US
Neal J. Meropol - Jenkintown PA, US
Richard L. Schilsky - LaGrange IL, US

A61K 38/20, A61P 35/00

424 852

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

7915043, Mar 29, 2011

Mar 20, 2006

11/908831

Michael A. Caligiuri - Columbus OH, US
Aharon G. Freud - Columbus OH, US
Michael B. Becknell - Westerville OH, US

The Ohio State University Research Foundation - Columbus OH

C12N 5/08

435372, 435375, 435383

The present invention provides isolated cells that are selectively enriched for hematopoietic progenitor cells that are precursors for natural killer (NK) cells. These cells are both CD34 and CD45RA positive and express C-integrin β, and are referred to as CD34CD45RAC-integrin β. The invention provides methods for isolating these cells, for inducing formation of CD56NK cells, and for treating diseases associated with immunodeficiency and cancer.

8530187, Sep 10, 2013

Mar 21, 2005

10/599194

Michael A. Caligiuri - Columbus OH, US
Rossana Trotta - Dublin OH, US
Jianhua Yu - Columbus OH, US
Brian Becknell - Westerville OH, US

The Ohio State University Research Foundation - Columbus OH

C12P 21/02

435 691, 4353723, 4353201, 4352351

Methods for stably transfecting mammalian natural killer cells comprising: transfecting a packaging cell line with a retroviral expression vector; culturing the transfected packaging cell line in a cell culture medium; and culturing the mammalian natural killer cells with the cell culture medium. Natural killer cells transfected according to the disclosed methods are also provided.

2007019, Aug 23, 2007

Nov 17, 2006

11/561363

Michael Caligiuri - Columbus OH, US
Robert Baiocchi - Dublin OH, US

The Ohio State University Research Foundation - Columbus OH

A61K 39/25, A61K 48/00, C12N 15/86, C12N 7/00, A61K 39/245

424229100, 514044000, 424230100, 435005000, 435456000, 435235100, 435325000

Methods of vaccination to prevent virus-associated diseases, which methods generally result in an increase of virus-specific memory T cells that provide or restore host immunity and result in control of the viral-associated disease process. Polypeptides and DNA sequences for achieving these results are also described. In some embodiments, the virus is Epstein-Barr virus.

2009000, Jan 1, 2009

Oct 12, 2005

11/577111

Robert A. Baiocchi - Columbus OH, US
Michael A. Caligiuri - Columbus OH, US
Anne M. Van Buskirk - Westerville OH, US

THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH

A61K 39/395, C12Q 1/68, C12Q 1/02

4241331, 4241581, 4241721, 435 6, 435 29

The disclosure relates to methods to prevent, treat, or slow the progression viral-associated lymphoproliferative disorders, EBV-associated lymphoproliferative disorders, and post-transplant lymphoproliferative disorders. In the methods, a TGF-β antagonist, e.g., an anti-TGF-β antibody is administered to a subject. Methods for treating viral-associated lymphoproliferative disorders and for enhancing T-cell responsiveness to a viral-associated lymphoproliferative disorder by administering a TGF-β antagonist are also described.

6042826, Mar 28, 2000

Nov 14, 1997

8/969881

Michael A. Caligiuri - Columbus OH
Robert B. Baiocchi - Columbus OH

Health Research, Inc. - Buffalo NY

A61K 39395, A61K 3816, C12P 2108, C07K 1600

4241301

A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking composition thereby inducing the lymphoma cells to undergo Fas-mediated cytotoxicity. The Fas-cross-linking composition may be an agonist anti-human Fas monoclonal antibody or fragments thereof, soluble Fas-ligand (Fas-L), and a combination thereof. In another embodiment, the lymphoma is pretreated with a composition that enhances Fas-mediated cytotoxicity induced by a Fas-cross-linking composition, followed by treatment with the Fas-cross-linking composition.